Artiva Biotherapeutics, Inc. (ARTV)
ARTV moved a median of -0.83% 30 minutes after news, and -1.73% by the close. How ARTV actually reacts to news — the realized, point-in-time move the market made, measured across 246 labeled events over the last three years with zero look-ahead.
ARTV’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.04% | 36% | 241 |
| 30-min | -0.83% | 42% | 242 |
| 60-min | -1.03% | 39% | 242 |
| to close | -1.73% | 35% | 237 |
| Middle 50% of ARTV reactions | -4.34% to +1.38% |
|---|---|
| Median reaction (30-min) | -0.83% |
| Measured reactions | 246 |
Half of all Artiva Biotherapeutics, Inc. news events land between -4.34% and +1.38% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ARTV reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 20 | -0.94% | 5% | 0.00% |
| Rating reiterations | 36 | +0.23% | 53% | -2.83% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how ARTV ranks against every other measured name →
That’s how ARTV usually reacts — get an email when it moves on news →Email me when ARTV moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ARTV's baseline. Nothing else.
Recent ARTV events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026 | Press release | GlobeNewswire | +0.94% | -0.87% | |
| Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026) | Press release | GlobeNewswire | -1.55% | -4.50% | |
| Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease | Press release | GlobeNewswire | -0.25% | -3.38% | |
| Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum | Press release | GlobeNewswire | +0.29% | -2.54% | |
| Form 8-K Artiva Biotherapeutics, For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +1.91% | -0.69% | |
| Form S-8 Artiva Biotherapeutics, | SEC filing · Form S-8 | SEC EDGAR | +1.91% | -0.69% | |
| Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026 | Press release | GlobeNewswire | -0.92% | +0.46% | |
| Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September | Press release | GlobeNewswire | +2.19% | +0.44% | |
| Form EFFECT Artiva Biotherapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -1.62% | +2.53% | |
| Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | +0.63% | -1.14% | |
| Form 10-Q Artiva Biotherapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.63% | -1.14% | |
| Form 8-K Artiva Biotherapeutics, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.63% | -1.14% | |
| Form S-3 Artiva Biotherapeutics, | SEC filing · Form S-3 | SEC EDGAR | +0.63% | -1.14% | |
| Form ARS Artiva Biotherapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +2.45% | +4.43% | |
| Form DEF 14A Artiva Biotherapeutics, For: Sep 08 | SEC filing · Form DEF | SEC EDGAR | +2.45% | +4.43% | |
| Form 8-K Artiva Biotherapeutics, For: Jul 22 | SEC filing · Form 8-K | SEC EDGAR | +2.70% | +4.33% | |
| Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.79% | +9.79% | |
| Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference | Press release | GlobeNewswire | +1.69% | -5.86% | |
| Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today | Press release | GlobeNewswire | -2.05% | -6.98% | |
| The $13 Million Company Teaching the Immune System to Hunt Cancer | Press release | Canada Newswire | -6.06% | -5.82% | |
| Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +1.61% | -0.13% | |
| Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases | Press release | GlobeNewswire | +1.24% | -11.31% | |
| Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development | Press release | GlobeNewswire | -0.04% | -5.53% | |
| Form 8-K Artiva Biotherapeutics, For: May 18 | SEC filing · Form 8-K | SEC EDGAR | -0.04% | -5.53% | |
| Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026 | Press release | GlobeNewswire | -3.60% | -10.00% | |
| Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -3.60% | -10.00% | |
| Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | -3.60% | -10.00% | |
| Form 10-Q Artiva Biotherapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -3.60% | -10.00% | |
| Form 8-K Artiva Biotherapeutics, For: May 08 | SEC filing · Form 8-K | SEC EDGAR | -3.60% | -10.00% | |
| Form 10-K/A Artiva Biotherapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.03% | +5.57% | |
| Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | -0.43% | -10.94% | |
| Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | -0.33% | +16.50% | |
| Form 10-K Artiva Biotherapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.33% | +16.50% | |
| Form 8-K Artiva Biotherapeutics, For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | -0.33% | +16.50% | |
| Form S-8 Artiva Biotherapeutics, | SEC filing · Form S-8 | SEC EDGAR | -0.33% | +16.50% | |
| Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | -2.46% | -0.79% | |
| Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant | Press release | GlobeNewswire | +0.00% | +5.68% | |
| Form 8-K Artiva Biotherapeutics, For: Feb 18 | SEC filing · Form 8-K | SEC EDGAR | -2.46% | -0.79% | |
| Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors | Press release | GlobeNewswire | +0.00% | +8.89% | |
| Form 8-K Artiva Biotherapeutics, For: Feb 18 | SEC filing · Form 8-K | SEC EDGAR | -1.61% | +3.31% | |
| Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability | Press release | GlobeNewswire | +1.29% | +1.93% | |
| Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines | Press release | PR Newswire | +0.00% | -1.29% | |
| Form 8-K Artiva Biotherapeutics, For: Dec 10 | SEC filing · Form 8-K | SEC EDGAR | +8.68% | +54.03% | |
| Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease | Press release | GlobeNewswire | +3.06% | +10.86% | |
| Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | +3.06% | +10.86% | |
| Form 10-Q Artiva Biotherapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.06% | +10.86% | |
| Form 8-K Artiva Biotherapeutics, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +3.06% | +10.86% | |
| Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK® | Press release | GlobeNewswire | +1.60% | -4.01% | |
| Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November | Press release | GlobeNewswire | +2.00% | +4.25% | |
| Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update | Press release | GlobeNewswire | -5.30% | +7.32% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ARTV section they belong to.
Where else ARTV is measured.
ARTV earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Artiva Biotherapeutics, Inc.'s median reaction calculated?
Every labeled ARTV news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 246 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of ARTV's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ARTV's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.